短報
本邦におけるGenotype1b・C型慢性肝炎に対するPeginterferon α-2a+Ribavirin併用療法とPeginterferon α-2b+Ribavirin併用療法の早期ウイルス学的反応の検討
2009 年 50 巻 10 号 p. 584-587
詳細
2009 年 50 巻 10 号 p. 584-587
We investigated the early virological response (EVR) to peginterferon (Peg-IFN) α-2a plus ribavirin (RBV) and Peg-IFNα-2b plus RBV therapy in 125 Japanese patients infected with hepatitis C virus (HCV) genotype1b. The rate of EVR, defined as HCV-RNA undetectable by COBAS TaqMan HCV test at 12 weeks after the start of treatment, was not significantly different between Peg-IFNα-2a plus RBV therapy and Peg-IFNα-2b plus RBV therapy (50.0% vs. 52.4%). However, the effect of previous interferon therapy did not influence the EVR rate in both groups. Multiple regression analysis showed that only serum albumin concentration (>4.1 g/dL) was a factor to contribute EVR. Further investigation is necessary, to compare the SVR rate, adverse events, and those in extended combination therapy between the two groups.
